Literature DB >> 11812902

Cardiovascular calcification in end-stage renal disease.

Isidro B Salusky1, William G Goodman.   

Abstract

Cardiovascular diseases are common in patients with end-stage renal disease (ESRD) and cardiovascular morbidity and mortality among dialysis patients are substantially higher than in the general population. The reasons for this high incidence are multiple. They include traditional factors such as hypertension, diabetes, dyslipidaemia, sodium overload, and elevated homocysteine levels as well as disturbances of mineral metabolism, specifically abnormalities in phosphorus and calcium homeostasis. This review will describe the specific cardiovascular complications related to calcifications in ESRD, the implications of the abnormalities of mineral metabolism in its pathogenesis and the current imaging techniques available for the detection of cardiovascular calcifications. Excess of calcium load contributes to the development of cardiac calcifications; therefore, alternative strategies to diminish exogenous calcium load should be considered in patients with ESRD.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11812902     DOI: 10.1093/ndt/17.2.336

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  16 in total

1.  Dyspnea in hemodialysis and early echocardiographic examination at the bedside: Two case reports.

Authors:  L Di Lullo; F Floccari; A Granata; F Fiorini; P Polito
Journal:  J Ultrasound       Date:  2011-06-28

2.  FGF-23 levels are associated with vascular calcification, but not with atherosclerosis, in hemodialysis patients.

Authors:  Mehmet Nuri Turan; Fatih Kircelli; Mustafa Yaprak; Ali Riza Sisman; Ozkan Gungor; Selen Bayraktaroglu; Mehmet Ozkahya; Gulay Asci; Jurgen Floege; Ercan Ok
Journal:  Int Urol Nephrol       Date:  2016-02-10       Impact factor: 2.370

3.  Oral active vitamin d treatment and mortality in maintenance hemodialysis patients.

Authors:  Shukun Wu; Junru Wang; Fang Wang; Li Wang
Journal:  Cardiorenal Med       Date:  2014-10-22       Impact factor: 2.041

Review 4.  Health-economic comparison of paricalcitol, calcitriol and alfacalcidol for the treatment of secondary hyperparathyroidism during haemodialysis.

Authors:  Hubertus Rosery; Rito Bergemann; Steven E Marx; Axel Boehnke; Joel Melnick; Raimund Sterz; Laura Williams
Journal:  Clin Drug Investig       Date:  2006       Impact factor: 2.859

5.  Nanoparticle targeting to diseased vasculature for imaging and therapy.

Authors:  Aditi Sinha; Aleksey Shaporev; Nasim Nosoudi; Yang Lei; Alexey Vertegel; Susan Lessner; Naren Vyavahare
Journal:  Nanomedicine       Date:  2014-02-22       Impact factor: 5.307

6.  Dietary phosphorus reduction by pretreatment of human breast milk with sevelamer.

Authors:  Elizabeth Ferrara; Jacques Lemire; Vivian M Reznik; Paul C Grimm
Journal:  Pediatr Nephrol       Date:  2004-04-22       Impact factor: 3.714

Review 7.  [Therapy and prophylaxis of renal failure].

Authors:  V M Brandenburg; B Heintz; J Floege
Journal:  Internist (Berl)       Date:  2003-07       Impact factor: 0.743

8.  Effects of atorvastatin on warfarin-induced aortic medial calcification and systolic blood pressure in rats.

Authors:  Chengyun Liu; Jingjing Wan; Qunfang Yang; Benling Qi; Wen Peng; Xuelin Chen
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2008-10-10

9.  Differences between hospitals in attainment of parathyroid hormone treatment targets in chronic kidney disease do not reflect differences in quality of care.

Authors:  Mieke J Peeters; Arjan D van Zuilen; Jan A J G van den Brand; Peter J Blankestijn; Marc A G J ten Dam; Jack F M Wetzels
Journal:  BMC Nephrol       Date:  2012-08-06       Impact factor: 2.388

10.  Vascular calcification on plain radiographs is associated with carotid intima media thickness, malnutrition and cardiovascular events in dialysis patients: a prospective observational study.

Authors:  Won Suk An; Young Ki Son
Journal:  BMC Nephrol       Date:  2013-01-29       Impact factor: 2.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.